GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evogene Ltd (XTAE:EVGN) » Definitions » Shiller PE Ratio

Evogene (XTAE:EVGN) Shiller PE Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Evogene Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Evogene Shiller PE Ratio Historical Data

The historical data trend for Evogene's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evogene Shiller PE Ratio Chart

Evogene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 13.27 - -

Evogene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Evogene's Shiller PE Ratio

For the Biotechnology subindustry, Evogene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evogene's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evogene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Evogene's Shiller PE Ratio falls into.



Evogene Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Evogene's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Evogene's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.296/131.7762*131.7762
=-0.296

Current CPI (Mar. 2024) = 131.7762.

Evogene Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.482 100.560 -0.632
201409 -0.630 100.428 -0.827
201412 -0.704 99.070 -0.936
201503 -0.482 99.621 -0.638
201506 -0.741 100.684 -0.970
201509 -0.482 100.392 -0.633
201512 -0.815 99.792 -1.076
201603 -0.482 100.470 -0.632
201606 -0.667 101.688 -0.864
201609 -0.741 101.861 -0.959
201612 -0.964 101.863 -1.247
201703 -0.704 102.862 -0.902
201706 -0.667 103.349 -0.850
201709 -0.741 104.136 -0.938
201712 -0.889 104.011 -1.126
201803 -0.778 105.290 -0.974
201806 -0.704 106.317 -0.873
201809 -0.704 106.507 -0.871
201812 -0.852 105.998 -1.059
201903 -0.556 107.251 -0.683
201906 -0.593 108.070 -0.723
201909 -0.593 108.329 -0.721
201912 -0.889 108.420 -1.081
202003 -0.889 108.902 -1.076
202006 -0.593 108.767 -0.718
202009 -0.630 109.815 -0.756
202012 -0.926 109.897 -1.110
202103 -0.630 111.754 -0.743
202106 -0.556 114.631 -0.639
202109 -0.704 115.734 -0.802
202112 -0.667 117.630 -0.747
202203 -0.741 121.301 -0.805
202206 -0.778 125.017 -0.820
202209 -0.593 125.227 -0.624
202212 -0.259 125.222 -0.273
202303 -0.556 127.348 -0.575
202306 -0.630 128.729 -0.645
202309 -0.296 129.860 -0.300
202312 -0.482 129.419 -0.491
202403 -0.296 131.776 -0.296

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Evogene  (XTAE:EVGN) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Evogene Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Evogene's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Evogene (XTAE:EVGN) Business Description

Traded in Other Exchanges
Address
13 Gad Feinstein Street, Park Rehovot, P.O. Box 4173, Ness Ziona, Rehovot, ISR, 7414002
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.